Latest News
Efficiency vs. Resilience: The Defining Life Sciences Battle of 2027
Tension is building in the life sciences industry as companies are asked to do more with less, while balancing efficiency and resilience. In the U.S., healthcare costs are rising faster than the economy, putting pressure on pricing and reimbursement [1]. Investors are...
Latest News
GLP-1s in Adolescents: What the Paediatric Obesity Evidence Shows
The case for GLP-1s in adolescents with obesity now rests on several randomised trials and two marketing authorisations. Real-world data are growing too. That evidence shows substantial reductions in body mass index over 56 to 68 weeks. It says much less about years...
Eppendorf and BioLabs Expand Collaboration to Munich
The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...
Divarasib Approval: When Could Roche’s KRAS Inhibitor Reach Patients?
Divarasib approval has no confirmed date, but Roche’s own guidance points to 2027. Roche’s Pharma Day slides of 28 September 2026 list US and EU approval as a 2027 milestone. No regulatory filing for the KRAS G12C inhibitor had been announced in the sources reviewed...
Beyond Screen Time: How Digital Habits Shape Attention and Memory
As digital platforms make information increasingly accessible, the challenge is no longer simply how much we consume, but how our digital habits affect the way we process, retain, and use it. Scrolling through social media can expose us to hundreds of pieces of...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Weekly News Roundup | 07 September 2026
Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...
Alexander Disease Treatment Approved: What It Means for UK Access
The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven
Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
ACTO Achieves Veeva Gold Product Partner Status
Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...
Huntington Gene Therapy Submission Reaches FDA and MHRA
uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...
GLP-1 Indications: The 2026 Regulatory Status Map
The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...
AI in MedTech: Accelerating the Product Development Lifecycle
Developing a new medical device is a lengthy, complex process that typically takes between three to seven years from conception to market [1]. For MedTech companies operating within highly regulated environments where compliance and patient safety are paramount,...
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Weekly News Roundup | 07 September 2026
Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...
Alexander Disease Treatment Approved: What It Means for UK Access
The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven
Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
ACTO Achieves Veeva Gold Product Partner Status
Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...
Huntington Gene Therapy Submission Reaches FDA and MHRA
uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...
GLP-1 Indications: The 2026 Regulatory Status Map
The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...
AI in MedTech: Accelerating the Product Development Lifecycle
Developing a new medical device is a lengthy, complex process that typically takes between three to seven years from conception to market [1]. For MedTech companies operating within highly regulated environments where compliance and patient safety are paramount,...
Featured Articles
Further News
Avacopan UK Suspension Follows Retracted Trial Data
The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...
Midlife Metabolic Change: How Behaviour, Nutrition and Stress Shape Health
Midlife marks one of the most significant physiological transitions in the human lifespan. For many individuals, particularly those navigating perimenopause and menopause, metabolic stability becomes harder to maintain, appetite signals shift, energy becomes less...
UK Animal Testing Deadline: What December Actually Requires
The UK animal testing deadline that matters most falls at the end of December. By then, regulatory testing on animals for skin irritation, eye irritation and skin sensitisation is meant to stop. It is the largest of a cluster of targets the Replacing Animals in...
AI in IVF: Ethical and Legal Limits of Algorithmic Decision-Making
AI embryo selection tools can support clinical judgment, but current evidence does not justify treating an algorithmic score as a clinical verdict. A prediction is not a decision Artificial intelligence is entering in vitro fertilisation at one of its most...
Autoimmune CAR-T Safety Under Review as Novartis Halts Eight Trials
Autoimmune CAR-T safety has moved to the centre of the cell therapy agenda. Novartis has halted eight clinical studies of its experimental CD19 CAR-T therapy rapcabtagene autoleucel. The company acted after three fatal cases of a severe inflammatory reaction. Bristol...
What a Hospitalist’s Floor Sees That Health AI Doesn’t
Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...
Screen Failures Are Data Too: What They Reveal About Trial Design
A single screen failure tells us something about a patient. A pattern of screen failures may tell us something about the trial. Clinical research is very good at studying the patients who make it into a trial. We analyze their baseline characteristics, laboratory...
Licensing versus Acquisition: How Pharma Chooses
On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...
Lilly Merida Acquisition Bets $2.875bn on Autoantibody Degraders
Eli Lilly has agreed to buy Merida Biosciences for up to $2.875 billion in cash. The Lilly Merida acquisition was announced on 31 August 2026. It hands Lilly a clinical stage platform built to strip single disease causing antibodies out of circulation. The lead...
ADHD Management for the Entire Active Day is Within Reach
When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...
Weekly News Roundup | 31 August 2026
Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...
Terpenes and Cytokine Modulation: The Evidence Gap in Clinical Aromatherapy
Inflammation is one of the most extensively studied biological processes in modern health science—and one of the most misunderstood concepts in clinical aromatherapy, natural-products and beauty. Inflammation is not inherently harmful. It is a coordinated biological...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













